Table 1:
Description of studies of ART-experienced individuals living with HIV-1—ART histories and HIV-1 pol sequence availability
| Number of individuals | Number of studies | Sequence and treatment availability | ||
|---|---|---|---|---|
| Number of individuals with available sequences (%) | Number of individuals with available linked sequences and treatment (%) | |||
| WHO-recommended first-line NNRTI-containing regimens (n=160 studies) * | ||||
| Zidovudine or stavudine | 12567 | 104 | 6110 (48·6%) | 4393 (35·0%) |
| Tenofovir | 7995 | 54 | 7360 (92·1%) | 6587 (82·4%) |
| Abacavir | 181 | 11 | 160 (88·4%) | 76 (42·0%) |
| ≥2 NRTIs | 416 | 8 | 416 (100%) | 416 (100%) |
| Uncertain† | 5633 | 42 | 3675 (65·2%) | 0 (0%) |
| Total | 26 792 | ·· | 17721 (66·1%) | 11472 (42·8%) |
| PI-containing regimens in previously PI-naive individuals (n=91 studies) * | ||||
| Lopinavir-ritonavir | 2182 | 43 | 1459 (66·9%) | 1170 (53·6%) |
| Atazanavir-ritonavir | 744 | 17 | 375 (50·4%) | 229 (30·8%) |
| Darunavir-ritonavir | 424 | 15 | 111 (26·2%) | 111 (26·2%) |
| ≥2 PIs or older PIs | 110 | 9 | 78 (70·9%) | 4 (3·6%) |
| Uncertain† | 4027 | 33 | 1803 (44·8%) | 0 (0%) |
| Total | 7487 | ·· | 3826 (51·1%) | 1514 (20·2%) |
| Second-generation NNRTI-containing regimens in previously NNRTI-naive individuals (n=14 studies) | ||||
| Rilpivirine | 110 | 2 | 0 (0%) | 0 (0%) |
| Etravirine | 0 | 0 | 0 (0%) | 0 (0%) |
| Doravirine | 7 | 1 | 0 (0%) | 0 (0%) |
| ≥2 NNRTIs | 1053 | 3 | 14 (1·3%) | 14 (1·3%) |
| Uncertain† | 250 | 8 | 0 (0%) | 0 (0%) |
| Total | 1420 | ·· | 14 (1·0%) | 14 (1·0%) |
| INSTI-containing regimens in previously INSTI-naive individuals (n=62 studies) * | ||||
| Raltegravir | 2818 | 34 | 1223 (43·4%) | 1199 (42·5%) |
| Elvitegravir | 334 | 11 | 224 (67·1%) | 224 (67·1%) |
| Dolutegravir | 154 | 15 | 113 (73·4%) | 113 (73·4%) |
| Bictegravir | 8 | 3 | 0 (0%) | 0 (0%) |
| ≥2 INSTIs | 209 | 14 | 158 (75·6%) | 158 (75·6%) |
| Uncertain† | 579 | 4 | 9 (1·6%) | 0 (0%) |
| Total | 4102 | ·· | 1727 (42·1%) | 1694 (41·3%) |
| Uncertain or unspecific regimens (n=125 studies) | ||||
| Total | 100143 | 125 | 15811 (15·8%) | 276 (0·3%) |
ART=antiretroviral therapy. INSTI=integrase strand transfer inhibitor. NRTI=nucleoside reverse transcriptase inhibitor. NNRTI=non-nucleoside reverse transcriptase inhibitor. PI=protease inhibitor.
*
The sum of the number of studies for each regimen is greater than n because some studies included individuals receiving different regimens.
†
Number of individuals in studies for which the number of individuals for each regimen was not described or the number of individuals with previous exposure to the drug class was not available.